Nafdac releases the names of the suspended products withdrawn in Nigeria *Complete list

The National Agency for Food and Drug Administration and Control (Nafdac) has announced the withdrawal, suspension or cancellation of registration certificates for 101 pharmaceutical products.

The Agency has announced on Tuesday 30 September through its official website, stating that the products concerned are no longer authorized for production, import, export, distribution, advertising, sale or use in Nigeria.

According to Nafdac, a registration certificate can be withdrawn when the market authorization owner voluntarily interrupts the use of the product. It can be suspended when the conditions on which the certificate has been issued are no longer satisfied, pending a final decision by the Agency. A certificate is canceled when it is completely revoked by Nafdac.

Of the 101 products, only four have been deleted, all belonging to Gentle Hills Limited, while the rest was voluntarily withdrawn by their authorization holders. The breakdown of the articles concerned shows a strong concentration between some key pharmaceutical companies. Servier Pharmaceutical Development Ltd recorded the highest number, with 25 products concerned. Healthline Limited followed six, while MSD Idea Pharmaceuticals Nigeria Ltd and Pfizer Specialties Limited had five. Other list of the list included Sanopi Aventis Nigeria Ltd, Fensyl Mhp Consulting Ltd, Blooms Pharmaceutical Ltd, Novartis Nigeria Limited, Astrazeneca Nigeria Limited, Glaxosmithkline Pharmaceutical Nigeria Ltd, Novo Nordisk Pharma, Janssen Pharmaceutical Companies and different and different smaller conductors.

The products are largely concentrated on chronic and infectious treatments. The drugs for cardiovascular conditions, in particular those containing perindopril and its various combinations such as Coveram, Coversyl and Triveram, had more in the foreground with twelve voices. The combination of atorvastatin and perindopril alone represented five. Diabetes drugs were also prominent, in particular those with sitagliptin or saxagliptin, alone or in combination with metformin, which has appeared several times. In the area of ​​infectious diseases, antimalaric drugs such as Artesunato/Amodiaquina and ArteMether/Lumefantrine have appeared repeatedly, as well as some antiretroviral combinations such as Lamivudine, Nevirapine and Zidovudine.

Other medicines in the list included nasal decongestants containing Ossimetazoline hydrochloride, antipsychotic treatments such as Paliperidone and antihypertensive drugs such as Valsartan.

Most of the products concerned were in the form of tablet, which represented almost three quarters of the list. Also syrups, suspensions, injectable and spray have appeared, although less frequently, while the capsules and eyes constituted the smallest proportion.

Nafdac urged the public, distributors and healthcare professionals to take note of the update and guarantee full compliance.